Roche CDx CAP - CLIA Laboratory
Roche CDx CAP - CLIA Laboratory is recorded as a service provider in 3 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 3 of 3 trials · Latest update first
A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects with Locally Advanced or Metastatic Solid Tumors that Harbor MET Amplification
Sponsor AbbVie Deutschland GmbH & Co. KG
- Start (EU)
- Latest update
- Estimated end
MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, Multicenter, Open-Label, Multi-Cohort, First-in Human Trial of DS3790a, a DXd-ADC targeting CD37, for Hematological Malignancies.
Sponsor Daiichi Sankyo Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Roche CDx CAP - CLIA Laboratory?
The 2026-10-09 snapshot links Roche CDx CAP - CLIA Laboratory to 3 distinct CTIS trials. Recorded services include Laboratory services. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Roche CDx CAP - CLIA Laboratory?
The most frequently recorded therapeutic areas are Solid Tumor Oncology. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Roche CDx CAP - CLIA Laboratory conducted?
The linked trials record locations in 9 countries, including France, Spain, Italy, Germany, Denmark. These are trial locations, not confirmed office locations or countries where Roche CDx CAP - CLIA Laboratory delivered services.
What can this page tell me about Roche CDx CAP - CLIA Laboratory's trial experience?
Browse 3 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Roche CDx CAP - CLIA Laboratory. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Roche CDx CAP - CLIA Laboratory